Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Nuevo parche cardíaco capaz de regenerar tejido cardíaco humano después de un infarto de miocardio


Oferta Tecnológica
Una empresa británica especializada en diseñar hidrogeles de péptidos para aplicaciones biomédicas y biotecnológicas ha desarrollado un nuevo parche cardíaco capaz de regenerar tejido cardíaco humano después de un infarto de miocardio (ataque al corazón). El parche está compuesto por poliuretano elastomérico en el que se inmoviliza un composite polimérico de policaprolactona/natural. El ensamble de ambos ofrece un parche sintético con las propiedades mecánicas y resistencia necesarias para ofrecer soporte mecánico al miocardio. La empresa busca organismos con el fin de comercializar la tecnología en todo el mundo mediante acuerdos de joint venture, licencia o fabricación.


Novel cardiac patch capable of regenerating human heart tissue after myocardial infraction (heart attack)
This North West UK based company specialises in the design of peptide hydrogels for biomedical and biotechnological applications. The company has developed a novel cardiac patch capable of regenerating human heart tissue after myocardial infraction (heart attack).

The company is looking for organisations to commercialize this technology worldwide via joint venture, licensing or manufacturing agreements.
This research focused UK based SME specialises in bespoke design and use of animal free biocompatible and biodegradable hydrogels with tailored properties and functionalities. The hydrogels are suitable as scaffolds for cell based therapies and assays, drug delivery vehicles as well as tissue engineering, thereby enabling the next generation of therapeutic treatments. Their hydrogels come in 3 basic formats; sprayable, injectable or part of a system of composites.

Recently, with support from UK universities the company has developed a novel cardiac patch for the regeneration of human heart tissue after myocardial infarction (heart attack).

The proposed patch is a component system composed of an elastomeric polyurethane onto which is immobilised a polycaprolactone/natural polymer composite. The assembly of both provide a synthetic patch which has the required mechanical properties and resilience to provide a mechanical support to the infarcted myocardium. The aforementioned assembly is decorated with a third element, a peptidic hydrogel to provide a suitable extracellular matrix (ECM) like microenvironment to interface with the tissue onto which the device is applied.

The device has been demonstrate in animal models to reverse the remodelling of the left ventricule. The hydrogel can be functionalised with cellular or acellular material to promote tissue regeneration through either repopulation of the lesion or by recruiting quiescent or circulating adult stem cells within the patient. Under such condition, the cardiac patch is a combination product. All polymeric components of the cardiac patch are biocompatible and biodegradable. No such product exist on the market.

The cardiac patch has been successfully tested in small and large animal models in pre-clinical settings.

The company is looking for partner(s) to identify the best way of offering this technology to save patients´ lives. The company is interested in joint venture, licensing and/or manufacturing agreements.
Advantages and Innovations:
Healthcare providers are seeking innovative ways to reduce the operating room time and the need for second surgery in cardiac, great vessel, and peripheral and vascular reconstruction. The current solutions available are either in the form of medication or in the most cases in organ transplantation.

A rehabilitation of the patient is possible to an extent after non-lethal coronary infarction, but larger impairments can´t be healed. Cardiac catheterization and angioplasty to dislodge the clot and open the blocked vessel have proven effective in restoring blood flow, but cannot reverse pre-existing tissue damage.

This highly innovative solution is made up of polymeric scaffold components which have been selected among synthetic and natural polymers, all of them having the singularity of been simultaneously biocompatible and biodegradable.

The proposed cardiac patch is to serve as mechanical support to the contractile muscle and reduce ventricle dilatation. The device is easy to handle and highly compatible with cellular therapies for cell delivery and confinement, hereby allowing tissue formation in damaged area which is not possible with existing solutions.
Stage of Development:
Already on the market
Patents granted

Partner sought

Type and Role of Partner Sought:
The company is looking for both:
· Hospitals
· or companies (SMEs, MNEs)

The cooperation type envisaged is joint venture, licensing and/or manufacturing agreement. The main role of the potential partner(s) would be to promote this technology in their country.

The company is particularly seeking partners with experience in penetrating markets with high value products and that have enough resources to support the commercialisation.

Any interest from the hospitals or national trusts will be addressed through licensing agreements.


Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
Languages Spoken:


Restrict dissemination to specific countries:
Argentina, Austria, Belgium, Brazil, Canada, China, Croatia, Czech_Republic, Denmark, Finland, France, Germany, Greece, Hungary, Iceland, India, Ireland, Italy, Korea, Republic Of, Lithuania, Malta, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Singapore, Spain, Sweden, Switzerland, Taiwan, Province Of China, United States


Technology Keywords:
06002002 Biología celular y molecular
06001024 Biomateriales médicos
06001011 Enfermedades circulatorias y del corazón
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06001019 Tecnologías de células madre